Aradigm Corporation (NASDAQ:ARDM) posted its earnings results on Thursday. The company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.37, Bloomberg Earnings reports. The business had revenue of $7.68 million during the quarter. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 1,515.94%.

Aradigm Corporation (NASDAQ:ARDM) traded up 6.8779% during trading on Friday, hitting $1.4001. The company had a trading volume of 131,850 shares. The stock has a 50-day moving average of $1.34 and a 200 day moving average of $1.52. Aradigm Corporation has a one year low of $0.78 and a one year high of $7.19. The company’s market capitalization is $20.73 million.

Separately, Zacks Investment Research upgraded Aradigm Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/11/aradigm-corporation-nasdaqardm-releases-quarterly-earnings-results-beats-estimates-by-0-37-eps.html.

About Aradigm Corporation

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Earnings History for Aradigm Corporation (NASDAQ:ARDM)

Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.